Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...

The "Chronic Urticaria: Competitive Landscape" report has been added tAndMarkets.com's offering.This report provides a data-driven overview of the current and future competitive landscape in chronic ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

On Tuesday night, October 1st, at a gala event held at Gotham Hall in New York City, PM360 announced the winners of its 16th annual Trailblazer Awards. In total, PM360, a leading life sciences ...

Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

AbbVie (ABBV) has lowered its 2024 earnings forecast by $0.04 per share due to the impact of certain expenses it expects to ...

Japan Pruritus Therapeutics Market was valued at US$ 582.2 million in 2023 and is estimated to surpass the market size of US$ 1,011.5 million by 2032 at a CAGR of 6.33% during the forecast period 2024 ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major cause of blood infections.

External affairs minister S Jaishankar meets with Sajith Premadasa, Sri Lanka's opposition leader, during his visit to Colombo. Jaishankar is the first foreign dignitary to visit since the NPP ...

Blasts Shake Beirut as Israel Targets Hezbollah Leaders, Officials Say Israeli officials said planes bombed a bunker where senior Hezbollah officials were meeting, including the presumed successor ...